Last reviewed · How we verify

Medicago — Portfolio Competitive Intelligence Brief

Medicago pipeline: 2 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 3 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intramuscular injection Intramuscular injection marketed
Intramuscular vaccine Intramuscular vaccine marketed
Fluarix Quadrivalent® Comparator Vaccine Fluarix Quadrivalent® Comparator Vaccine phase 3 Inactivated influenza vaccine Immunology
Quadrivalent VLP Influenza Vaccine Quadrivalent VLP Influenza Vaccine phase 3 Quadrivalent influenza vaccine Influenza hemagglutinin and neuraminidase antigens Immunology / Infectious Disease
Quadrivalent VLP Vaccine Quadrivalent VLP Vaccine phase 3 Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigham and Women's Hospital · 1 shared drug class
  4. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  5. Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
  6. Folia Biotech Inc. · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Ab&B Bio-tech Co., Ltd.JS · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medicago:

Cite this brief

Drug Landscape (2026). Medicago — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medicago. Accessed 2026-05-13.

Related